Abstract:The two main pathological hallmarks of Parkinson's disease are loss of dopamine neurons in the substantia nigra pars compacta and proteinaceous amyloid fibrils composed mostly of α-synuclein, called Lewy pathology. Levodopa to enhance dopaminergic transmission remains one of the most effective treatment for alleviating the motor symptoms of Parkinson's disease (Olanow, Mov Disord 34:812-815, 2019). In addition, deep brain stimulation (Bronstein et al., Arch Neurol 68:165, 2011) to modulate basal ganglia circuit activity successfully alleviates some motor symptoms. MRI guided focused ultrasound in the subthalamic nucleus is a promising therapeutic strategy as well (Martinez-Fernandez et al., Lancet Neurol 17:54-63, 2018). However, to date, there exists no treatment that stops the progression of this disease. The findings that α-synuclein can be released from neurons and inherited through interconnected neural networks opened the door for discovering novel treatment strategies to prevent the formation and spread of Lewy pathology with the goal of halting PD in its tracks. This hypothesis is based on discoveries that pathologic aggregates of α-synuclein induce the endogenous α-synuclein protein to adopt a similar pathologic conformation, and is thus self-propagating. Phase I clinical trials are currently ongoing to test treatments such as immunotherapy to prevent the neuron to neuron spread of extracellular aggregates. Although tremendous progress has been made in understanding how Lewy pathology forms and spreads throughout the brain, cell intrinsic factors also play a critical role in the formation of pathologic α-synuclein, such as mechanisms that increase endogenous α-synuclein levels, selective expression profiles in distinct neuron subtypes, mutations and altered function of proteins involved in α-synuclein synthesis and degradation, and oxidative stress. Strategies that prevent the formation of pathologic α-synuclein should consider extracellular release and propagation, as well as neuron intrinsic mechanisms.

Prion-Like Mechanisms in Parkinson’s Disease

Prion-like Mechanisms in Alzheimer's Disease.

Alpha-Synuclein Aggregation in Parkinson's Disease

The role of α-synuclein prion strains in Parkinson's disease and multiple system atrophy

Structure, Distribution, and Genetic Profile of Α-Synuclein and Their Potential Clinical Application in Parkinson's Disease.

The Prion-Like Spreading of Alpha-Synuclein in Parkinson’s Disease: Update on Models and Hypotheses

Prion-Like Propagation of Protein Misfolding and Aggregation in Amyotrophic Lateral Sclerosis

Decoding the Cellular Trafficking of Prion-like Proteins in Neurodegenerative Diseases

Structural Variations of Prions and Prion-like Proteins Associated with Neurodegeneration

Initiation and propagation of α-synuclein aggregation in the nervous system

Aggregation States of α-Synuclein and Its Involvement in Parkinson’s Disease

Α-Synuclein Aggregation and Transmission in Parkinson’s Disease: a Link to Mitochondria and Lysosome

Prionoid Proteins in the Pathogenesis of Neurodegenerative Diseases

The role and mechanism of abnormal accumulation and transmission of alpha-synuclein in the pathogenesis and progression of Parkinson′s disease

Recent progress in prion and prion-like protein aggregation.

Attempt to Untangle the Prion-Like Misfolding Mechanism for Neurodegenerative Diseases

Protein aggregation and its affecting mechanisms in neurodegenerative diseases

α-Synuclein and Its Probable Mechanisms in Pathogenesis of Parkinson's Disease

Proaggregant Nuclear Factor(s) Trigger Rapid Formation of Α-Synuclein Aggregates in Apoptotic Neurons

Protein–protein interactions regulating α-synuclein pathology

Association of Glial Activation and Α-Synuclein Pathology in Parkinson’s Disease